Insider Selling: OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells $437,040.00 in Stock

Key Points

• Major shareholder Jennifer Pritzker sold 18,000 OrthoPediatrics shares for approximately $437,040, reducing her stake by 0.26% to 6.86 million shares valued at about $166.6 million.
• OrthoPediatrics shares traded at $24.03, near their 52-week high of $26.74. The company recently beat quarterly revenue and adjusted EPS expectations, reporting $70.51 million in revenue and an EPS loss of $0.26.
• Analysts maintain a generally positive outlook, with nine Buy ratings, one Hold and one Sell; the stock has a “Moderate Buy” consensus rating and an average price target of $26.44.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) major shareholder Jennifer Pritzker sold 18,000 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00. Following the completion of the sale, the insider owned 6,863,464 shares of the company's stock, valued at $166,644,905.92. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

OrthoPediatrics Stock Performance

KIDS stock traded down $0.47 during mid-day trading on Wednesday, reaching $24.03. 169,608 shares of the stock traded hands, compared to its average volume of 171,545. The business has a 50-day moving average of $21.11 and a two-hundred day moving average of $18.53. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The firm has a market capitalization of $627.42 million, a PE ratio of -14.30 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KIDS. Russell Investments Group Ltd. grew its holdings in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company's stock worth $26,000 after acquiring an additional 1,139 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of OrthoPediatrics during the second quarter worth approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company's stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. Caption Management LLC bought a new stake in shares of OrthoPediatrics during the third quarter valued at approximately $54,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,235 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

Analyst Ratings Changes

KIDS has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 5th. Needham & Company LLC upped their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. TD Cowen reissued a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research increased their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Finally, Truist Financial set a $22.00 target price on OrthoPediatrics in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source